• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ platform technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Our Value Proposition

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

Learn more about LAT™

May 10, 2018

Featured Publication

KemPharm Announces Positive, Topline Results from an IV Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Intravenous Human Abuse Potential Trial with KP415 Prodrug (KP415.A03) Clinical Findings: Following intravenous administration in recreational stimulant abusers, KP415 Prodrug demonstrated Drug Liking scores similar to placebo when administered up to the highest safe […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture
  • KemPharm Announces Positive, Topline Results from an IV Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

  • KemPharm, Inc. to Report First Quarter 2018 Results

  • KemPharm Reports Fourth Quarter and Year End 2017 Results